DrugInformations.org

Rising gas prices are affecting more than the family budget. More pain at the pump results in more employee stress on the job, says Wayne Hochwarter, the Jim Moran Professor of Management at Florida State University’s College of Business.”People concerned with the effects of gas prices were significantly less attentive on the job, less excited about going to work, less passionate and conscientious and more tense,” Hochwarter said.

More: continued here

No Comments »

With the war in Iraq in its sixth year and a new generation of veterans requiring care, Geisinger Health System will host a conference May 13 that brings together military and civilian experts to better understand and meet the unique challenges faced by rural soldiers and their families.

More: continued here

No Comments »

Real or perceived threats can trigger the well-known “fight or flight response” in humans and other animals. Adrenaline flows, and the stressed individual’s heart pumps faster, the muscles work harder, the brain sharpens and non-essential systems shut down. The whole organism responds in concert in order to survive.

More: continued here

No Comments »

Is medicated memory manipulation ethically sound? And perhaps more importantly, who should be charged with the decision to deliver such a treatment: patient or physician? Elisa Hurley, a philosophy professor, is seeking answers to these questions in her research currently underway at The University of Western Ontario.

More: continued here

No Comments »

Wouldn’t it be nice if our doctors could predict accurately whether we would respond to a particular medication? This question is important because research studies provide information about how groups of patients tend to respond to treatments, but inevitably, differences among groups of patients with the same diagnosis mean that findings about groups of patients may not apply to individuals from those groups.

More: continued here

No Comments »

Spreading rumors and gossiping may not cause bruises or black eyes, but the psychological consequences of this social type of bullying could linger into early adulthood, a new University of Florida study shows.

More: continued here

No Comments »

Next Pharmaceuticals announced the results of a six-week, double-blind, placebo-controlled clinical study on Relora conducted on healthy women between the ages of 20 and 50. Relora significantly reduced short-term anxiety compared to the placebo group. The study conducted by Miami Research Associates, a clinical research organization in Miami, Florida, was published in Nutrition Journal, an open access peer-reviewed, online journal.

More: continued here

No Comments »

AstraZeneca (NYSE:AZN) announced new study data on SEROQUEL XR? (quetiapine fumarate) Extended-Release Tablets (quetiapine XR) for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adult patients. The results from the studies were presented today at the 161st Annual Meeting of the American Psychiatric Association (APA) in Washington, DC.

More: continued here

No Comments »

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has completed the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. AZ-002 is an inhalation product candidate being developed for the acute treatment of panic attacks associated with panic disorder. AZ-002 is being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital in 2006.

More: continued here

No Comments »

A paper by Giovanni A. Fava and associates of the University of Bologna published in the April issue of Psychotherapy and Psychosomatics summarizes the evidence which supports the seriousness of agoraphobia as an invalidating disease. At the same time it questions the excessive emphasis on panic which has been attributed in the past decade and the role of pharmaceutical industry in this attribution.

More: continued here

No Comments »